Serving Lutz, Cheval, Carrollwood, Northdale, Odessa and Land O Lakes
(May 2001)
There is very little blood-flow to this tissue in the body
Evidence overview: see a pharmacology review in Curr Pharm Des for BPC157 mechanisms and models (preclinical) Curr Pharm Des review RUO status: Not FDAapproved as a drug
Protocol 5: neurological recovery support Goal: Support recovery from TBI, stroke, or other neurological injury Primary peptide: Cerebrolysin 10-20ml IM daily for 10-20 days (requires medical supervision) Alternatively: Semax 600-900mcg daily if Cerebrolysin unavailable Supporting peptide: BPC-157 500mcg twice daily for tissue healing Duration: Acute phase treatment, may repeat cycles as recovery progresses Considerations: Neurological injury recovery should involve medical supervision
Furthermore, we additionally challenged the most immediate period after injury induction (skin defect) (i.e., 2, 5, and 10 min) (Figure 8) due to the evidence that BPC 157 did ensure a particular specificity within the pathways (at least, Egr, Nos, Srf, Vegr, Akt1, Plc , and Kras genes) (Vukojevic et al., 2018)